The combination therapy primarily enhances anti-tumor activity by inhibiting the Wnt/β-catenin/CBP/c-myc signal, β-catenin nuclear translocation, and the AKT/p-AKT and ERK/p-ERK signaling pathways, independent of CTNNB1 mutation. The gene discussed is MYC; the disease is neoplasm.